For anyone in Duran trying to locate CJC-1295, the first thing to know is that this compound moves through online research channels. This online-only market structure is ultimately a quality advantage — top vendors compete on lab-verified purity in ways brick-and-mortar outlets simply cannot. Separating genuine research-grade CJC-1295 from the rest of the market depends on three things: an HPLC chromatogram documenting ≥98% purity, mass spec data verifying the correct molecular weight, and a batch-specific endotoxin panel. This guide gives Duran researchers the practical tools to assess vendor quality rigorously and source verified-quality CJC-1295 with confidence.
CJC-1295 Mechanisms Explained
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Duran researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
How to Source CJC-1295 — Vendor Guide
Vetting CJC-1295 vendors requires starting from the COA: request the batch-specific certificate before purchasing, not after. Mass spectrometry in the COA confirms that the main HPLC peak is actually CJC-1295 and not a structurally similar impurity — HPLC purity alone cannot verify molecular identity. Community reputation in research forums is a useful additional signal to COA verification — vendors with consistently positive reports over 12+ months have earned that standing through repeat quality delivery. Hold lyophilised CJC-1295 at freezer temperature (−20°C) until ready to use; reconstitute only the volume needed for upcoming use and keep the remainder frozen.
Order CJC-1295 — ships to Duran
COA-verified · International tracking · Research grade
CJC-1295 is sold for research purposes only and is not approved for human consumption by the FDA or comparable health authorities — all information here is educational. Proper handling of CJC-1295 requires careful sterile procedure — swabbed septum with alcohol prep pad, new needle for each draw, clean preparation area — and temperature control throughout the entire workflow. Endotoxin testing in the CJC-1295 COA is non-negotiable — gram-negative bacterial endotoxins can trigger severe inflammatory responses at trace quantities, and no pricing advantage justifies skipping this verification. Researchers combining CJC-1295 with other compounds should review the available literature for documented interactions before beginning combination research.
Frequently Asked Questions
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
